This study is looking at circulating tumor DNA (ctDNA) in people with pancreatic cancer that can be removed by surgery. ctDNA are tiny pieces of tumor DNA found in your blood. Researchers want to see how many patients have ctDNA and if having ctDNA is linked to how long patients live without their cancer growing (progression-free survival). The study will follow up to 50 patients who are receiving standard treatments like chemotherapy and surgery. The goal is to learn if ctDNA can help doctors better understand and treat pancreatic cancer in the future. You may be able to join if you are 18 to 99 years old, have newly diagnosed pancreatic cancer that can be removed by surgery, and have a good performance status (meaning you are able to do most daily activities). This study is currently recruiting patients.

Study design

This is an observational study involving up to 50 participants. It is a single-arm study, meaning all participants will receive the same study procedures, and there is no comparison group.

What's involved

You would have pre-study exams, including a doctor's visit, blood work, and imaging. During the study, you will receive your regular pancreatic cancer treatment, and blood will be drawn regularly for ctDNA detection. You will be followed for up to 2 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 2 years to measure progression-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.